Ferring Highlights Commitment to C. Diff Infection Community on the Second Anniversary of the Launch of REBYOTA® (fecal ...

FDA approved to prevent recurrent C. difficile infection (rCDI), REBYOTA is widely available with a strong drug supply and dedicated manufacturing facility Since launch, Ferring created REBYOTA ...

(MENAFN- EIN Presswire) Clostridium Difficile Infections companies working in market are Pfizer, Valneva, GlaxoSmithKline, Summit Therapeutics, MGB Biopharma, Acurx Pharmaceuticals. LAS VEGAS ...

Clostridium difficile infection (CDI) is a significant health concern, particularly in individuals who have recently undergone antibiotic treatment. CDI can lead to severe gastrointestinal issues ...

Recurrent Clostridium difficile (C diff) infection is a hard-to-treat gastrointestinal (GI) infection that causes 29,000 deaths every year in the US alone. Microbiome drug gets Breakthrough ...

Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix. The results from the open label phase 2 trial confirm that ...

A 2018 study of adults and children who were taking antibiotics and co-administered a probiotic supplement showed a lower risk of Clostridium difficile infections. The study authors concluded ...

Roche has obtained U.S. government green lights allowing its point-of-care testing system to be used to screen for multiple ...